Advice
Following a full submission
clopidogrel (Plavix®) is accepted for restricted use within NHS Scotland for patients with ST segment elevation acute myocardial infarction (MI), in combination with aspirin, in medically treated patients eligible for thrombolytic therapy.
The addition of short-term treatment with clopidogrel to long-term low dose aspirin has improved the patency rate of the infarct related artery as well as clinical endpoints. Treatment with clopidogrel in these patients is restricted to continuation for 4 weeks.
Download detailed advice54KB (PDF)
Medicine details
- Medicine name:
- clopidogrel 75mg tablets (Plavix)
- SMC ID:
- 390/07
- Indication:
- ST-segment elevation myocardial infarction (STEMI)
- Pharmaceutical company
- Sanofi-Aventis
- BNF chapter
- Cardiovascular system
- Submission type
- Full
- Status
- Restricted
- Date advice published
- 13 August 2007